Skip to content

The role of xanthine oxidoreductase combined with inflammatory factors and clinical features in assessing the prognosis of patients with severe neurological disease

The role of xanthine oxidoreductase combined with inflammatory factors and clinical features in assessing the prognosis of patients with severe neurological disease

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200056387
Enrollment
Unknown
Registered
2022-02-04
Start date
2022-03-01
Completion date
Unknown
Last updated
2024-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

traumatic brain injury

Interventions

TBI group:XOR Inhibitor
Control group:NA

Sponsors

Clinical Medical College of Yangzhou University, Northern Jiangsu People’s Hospital, Yangzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Clinical diagnosis by CT, MRI, etc.; 2. Admission to the hospital within 72 hours of the onset of illness; 3. GCS score of 3 to 8, that is, severe head injury with coma; 4. Aged 18 to 75 years; 5. Gender is not limited; 6. All close relatives and family members agree to conduct the study and sign a written informed consent form.

Exclusion criteria

Exclusion criteria: 1. With serious multiple injuries (fractures other than skulls, hemopsyothorax, hepatosplenyl pancreas and kidney rupture, etc.); 2. There is a history of serious infection or myocardial infarction within half a year; 3. Suffering from autoimmune diseases or blood diseases; 4. Severe language function or hearing impairment; 5. Previous head trauma, intracranial occupancy; 6. Patients with hemangiomas, vascular malformations, vasculitis and severe heart, lung, liver, kidney failure, pregnancy and known malignant tumors; 7. Persons with mental or serious psychological abnormalities; 8. Can not cooperate with the completion of various inspections.

Design outcomes

Primary

MeasureTime frame
serum level of XOR;GCS;mortality;

Secondary

MeasureTime frame
Blood pressure;heart rate;Hospital stay;Inflammatory factors;

Countries

China

Contacts

Public ContactLi Yuping

Clinical Medical College of Yangzhou University, Northern Jiangsu People’s Hospital, Yangzhou University

yupingli@yzu.edu.cn+86 18051062519

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026